Novo Nordisk rebrands to ‘Novo,’ CEO tells CNBC drugmaker needs to ‘rethink’ strategy amid obesity race

​ The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly. Read More

​ The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly. Read More

Leave a Reply

Your email address will not be published. Required fields are marked *